TITLE

Two simple approaches for validating a binary surrogate endpoint using data from multiple trials

AUTHOR(S)
Baker, Stuart G.
PUB. DATE
October 2008
SOURCE
Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p505
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A surrogate endpoint is an endpoint that is observed before a true endpoint and is used to draw conclusions about the effect of intervention on true endpoint. To gauge confidence in the use of a surrogate endpoint, it must be validated. Two simple validation methods using data from multiple trials with surrogate and true endpoints are discussed: an estimation method extending previous work and new method based on hypothesis tests. The validation methods were applied to two data sets, each involving 10 randomized trials: one for patients with early colon cancer where the true endpoint was survival status at eight years and surrogate endpoint was cancer recurrence status at three years, and one for patients with advanced colorectal cancer where the true endpoint was survival status at 12 months and the surrogate endpoint was cancer recurrence status at six months. The estimation method uses the surrogate endpoint in the new trial and a model relating surrogate and true endpoints in previous trials to predict the effect of intervention on true endpoint in the new trial. For validation, each trial was successively treated as the `new' trial and a comparison was made between predicted and observed effects of intervention on true endpoint. Performance of the surrogate endpoint was good in both data sets. The hypothesis testing method involves the z-statistic for the surrogate endpoint, which is the estimated effect of intervention on surrogate endpoint divided by its standard error. To use this z-statistic to test a null hypothesis of no effect of intervention on true endpoint, the critical value is increased above a standard level of 1.96 to a level determined by the relationships between surrogate and true endpoints in the data sets. This elevated critical value could be used for accelerated approval.
ACCESSION #
35355528

 

Related Articles

  • Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Alonso, Ariel; Molenberghs, Geert // Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p497 

    The last two decades have seen a lot of development in the area of surrogate marker validation. One of these approaches places the evaluation in a meta-analytic framework, leading to definitions in terms of trial- and individual-level association. A drawback of this methodology is that different...

  • Surrogate endpoint validation: statistical elegance versus clinical relevance. Green, E. M.; Yothers, G.; Sargent, Daniel J. // Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p477 

    A variety of approaches have been proposed to provide formal and informal validation of proposed surrogate markers. To achieve true clinical impact, the validation must convince both the statistical and clinical communities. In this paper, we argue that the best approach is not a single method...

  • Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective. Piedbois, Pascal; Croswell, Jennifer Miller // Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p519 

    Surrogate endpoints in oncology research and practice have garnered increasing attention over the past two decades. This activity has largely been driven by the promise surrogate endpoints appear to hold: the potential to get new therapies to seriously ill patients more rapidly. However,...

  • Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Grothey, Axel // Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p529 

    The administration of adjuvant chemotherapy after resection of stage III colon cancer to prolong disease-free survival (DFS) and increase overall survival (OS) has been clinical standard since the early 1990s. Recently, 3-year DFS was recognized as surrogate endpoint for OS based on a...

  • Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Chakravarty, Aloka; Sridhara, Rajeshwari // Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p515 

    There has been interest in using progression-free survival as a surrogate endpoint for overall survival in oncology clinical trials. In order to objectively define this endpoint, clear understanding of what progression means, how it is measured and what its implications are need to be discussed....

  • Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Hughes, Michael D. // Statistical Methods in Medical Research;Oct2008, Vol. 17 Issue 5, p487 

    This paper is based on a conference presentation in which several authors presented results from analyses of the same dataset concerning the evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival in advanced colorectal cancer clinical trials. In evaluating a...

  • Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials. Bünger, S.; Zimmermann, M.; Habermann, J. // Cancer & Metastasis Reviews;Sep2015, Vol. 34 Issue 3, p527 

    Hematogenous spreading of tumor cells from primary tumors is a crucial step in the cascade to metastasis, the latter being the most limiting factor for patients' survival prognosis. Therefore, circulating tumor cells (CTCs) have become a field of intensive research. However, the process of...

  • Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery. Mori, Koichiro; Toiyama, Yuji; Saigusa, Susumu; Fujikawa, Hiroyuki; Hiro, Junichiro; Kobayashi, Minako; Ohi, Masaki; Araki, Toshimitsu; Inoue, Yasuhiro; Tanaka, Koji; Mohri, Yasuhiko; Kusunoki, Masato // Digestive Diseases & Sciences;Aug2015, Vol. 60 Issue 8, p2477 

    Background: Preoperative serum systemic inflammatory response (SIR) in patients with colorectal cancer (CRC) has been reported to be a predictive biomarker of early recurrence. The molecular status of CRC, including microsatellite instability (MSI), BRAF and KRAS mutations, and...

  • Focus on 16p13.3 Locus in Colon Cancer. Mampaey, Evi; Fieuw, Annelies; Van Laethem, Thalia; Ferdinande, Liesbeth; Claes, Kathleen; Ceelen, Wim; Van Nieuwenhove, Yves; Pattyn, Piet; De Man, Marc; De Ruyck, Kim; Van Roy, Nadine; Geboes, Karen; Laurent, Stéphanie // PLoS ONE;7/29/2015, Vol. 10 Issue 7, p1 

    Background: With one million new cases of colorectal cancer (CRC) diagnosed annually in the world, CRC is the third most commonly diagnosed cancer in the Western world. Patients with stage I-III CRC can be cured with surgery but are at risk for recurrence. Colorectal cancer is characterized by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics